Rabih Fahed, MD
Hematology & Oncology · Norfolk, NENPI 1043488844
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $207,711 of the $294,122 with a category attached, or 70.6%. 60 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 50.3% of the total. Reporting peaked in 2019 at $87,503 and has fallen 81.2% since, to $16,489 in 2025. Among hematology & oncology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 538 payments — averaging $546.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$148K
- AstraZeneca$49K
- Bristol Myers Squibb$21K
- Regeneron Healthcare Solutions, Inc.$16K
- Seagen Inc.$10K
- Incyte Corporation$10K
- plus $39K from 54 others
What the payments were for
- Consulting fees$57,75020%
- Speaking & faculty fees$207,71171%
- Travel & lodging$19,5667%
- Food & beverage$8,5853%
- Education$5110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$294,122 in reported general payments places this provider in the 95th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 53 | $783,811 |
| Lenalidomide | 52 | $730,130 |
| JakafiRuxolitinib Phosphate | 26 | $452,540 |
| PomalystPomalidomide | 20 | $343,989 |
| VerzenioAbemaciclib | 17 | $250,251 |
| XtandiEnzalutamide | 16 | $250,114 |
| IbrancePalbociclib | 12 | $195,621 |
| VenclextaVenetoclax | 31 | $173,440 |
| PromactaEltrombopag Olamine | 11 | $136,754 |
| EliquisApixaban | 170 | $105,287 |
| Abiraterone Acetate | 69 | $86,606 |
| XareltoRivaroxaban | 43 | $24,083 |
| Enoxaparin Sodium | 27 | $7,322 |
| Anastrozole | 219 | $3,127 |
| Hydroxyurea | 64 | $1,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $48,976 | $783,81153 claims |
| Incyte CorporationJakafi | $9,771 | $452,54026 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $147,919 | $343,98920 claims |
| PfizerIbrance, Eliquis | $857 | $300,908182 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $74 | $250,709109 claims |
| Astellas Pharma US IncXtandi | $225 | $250,11416 claims |
| AbbVieVenclexta | $2,434 | $173,44031 claims |
| NovartisPromacta | $175 | $136,75411 claims |
| Johnson & JohnsonXarelto | $1,981 | $24,08343 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $22 | $1,600160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Norfolk
- Mojtaba AkhtariOmaha$1.8M
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
- Debora BrunoHastings$57K
- Pornchai JonglerthamHastings$48K
- Samer RennoOmaha$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.